An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms INSPIRE LTE
- Sponsors Sun Pharmaceutical Industries
- 02 Nov 2023 Status changed from active, no longer recruiting to recruiting.
- 05 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 08 Jul 2022 Status changed from not yet recruiting to recruiting.